Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.
Type:
Grant
Filed:
November 15, 2001
Date of Patent:
May 17, 2005
Assignee:
The Procter & Gamble Company
Inventors:
Gregory Paul Dittmar, Joseph Michael Amante, Tony Ryan Cronk, Daniel Gary Newby
Abstract: This invention pertains to a process for making a sustained release complex. Compound (I), which comprises Compound (A), having formula (A), and a copolymer comprising poly (l)-lactic-glycolic-tartaric acid (P(I)LGT), wherein the amino group of Compound (A) is ionically bound to a carboxyl group of the (P(I)LGT).
Abstract: This invention relates to fat containing consumable food products comprising ?-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without ?-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention.
Abstract: Cosmetic or personal care compositions, such as for styling hair, comprise a thermoplastic elastomer which is a block copolymer comprising a core polymer having a backbone comprising at least a proportion of C—C bonds and two or more flanking polymers. Each flanking polymer is covalently bound to an end of the core polymer and the core polymer and/or at least one of the flanking polymers is a copolymer derived from two or more monomers. The compositions comprise a cosmetically acceptable diluent or carrier.
Type:
Grant
Filed:
October 30, 2003
Date of Patent:
May 10, 2005
Assignee:
Unilever Home & Personal Care USA, division of Conopco, Inc.
Inventors:
Jean M. J. Frechet, Damian Hajduk, Ezat Khoshdel, Mingjun Liu, Ralph B. Nielsen, Euan Stuart Reid, Keith Leslie Rutherford
Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.
Type:
Grant
Filed:
November 14, 2002
Date of Patent:
May 10, 2005
Assignee:
Genzyme Corporation
Inventors:
Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.
Type:
Grant
Filed:
May 25, 2001
Date of Patent:
May 3, 2005
Assignees:
Medtronic Vascular, Inc., The United States of America as represented by the Department of Health and Human Services
Inventors:
Anthony L. Fitzhugh, Peiwen Cheng, Joseph Saavedra, Robert Cafferata, Marc Hendriks, Larry K. Keefer, Eugene Tedeschi, Michel I. P. M. Verhoeven
Abstract: A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of fillers having disintegrant properties in an amount higher than 35% w/w of the formulation.
Type:
Grant
Filed:
January 21, 2003
Date of Patent:
April 5, 2005
Assignee:
AstraZeneca AB
Inventors:
Sigbrit Forsman, Christer Karlsson, Magnus Karlsson
Abstract: PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small molecules, and others. These derivatives provide a sufficient circulation period for a drug-PEG conjugate and then for hydrolytic breakdown of the conjugate and release of the bound molecule. In some cases, drugs that previously had reduced activity when permanently coupled to PEG can have therapeutically suitable activity when coupled to a degradable PEG in accordance with the invention. The PEG of the invention can be used to impart water solubility, size, slow rate of kidney clearance, and reduced immunogenicity to the conjugate. Controlled hydrolytic release of the bound molecule in the aqueous environment can then enhance the drug delivery system.
Abstract: There is provided a method and associated kit for reducing the normal dosage of a pharmaceutical given to a patient for the treatment of a disorder without substantially reducing its effectiveness. During a first predetermined time period, a substantially full dosage of the pharmaceutical is administered to the patient, preferably with a placebo. During a second predetermined time period, a reduced dosage of the pharmaceutical is administered to the patient, also with a placebo. The second predetermined time period is subsequent to the first predetermined time period. Preferably, the placebo has a distinctive indicia. The placebo, in association with the decreased pharmaceutical, augments the effectiveness of the pharmaceutical by heightening the patient's conditioned response and expectation of effectiveness.
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one linker, and at least one molecular hook wherein the molecular hook comprises a heterocyclic trimethylpyrimidinium compound.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
February 1, 2005
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne, Alan Roy Katritzky, Jon Walter Merkert
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one linker, and at least one molecular hook wherein the molecular hook comprises a heterocyclic trimethylpyrimidinium compound.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
February 1, 2005
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne, Alan Roy Katritzky, Jon Walter Merkert
Abstract: This invention relates to methods of coating the lumenal surface of a blood vessel, or other tissue cavity, and to compositions suitable for use in same.
Type:
Grant
Filed:
February 7, 2002
Date of Patent:
February 1, 2005
Assignee:
Cryolife, Inc.
Inventors:
Jeremy Ollerenshaw, Umit Yuksel, Kirby S. Black
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one linker, and at least one molecular hook wherein the molecular hook comprises a heterocyclic trimethylpyrimidinium compound.
Type:
Grant
Filed:
October 17, 2002
Date of Patent:
January 18, 2005
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne, Alan Roy Katritzky, Jon Walter Merkert
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one linker, and at least one molecular hook wherein the molecular hook comprises a heterocyclic trimethylpyrimidinium compound.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
January 11, 2005
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne, Alan Roy Katritzky, Jon Walter Merkert
Abstract: The invention is relative to a pharmaceutical preparation, especially for oral administration, with at least one active substance and with formulation components influencing the release of active substance, which preparation comprises at least one opiod analgesic as active substance that is formulated proportionally on the one hand for rapid release and on the other hand for delayed release in such a manner that the in vitro release rate from the preparation according to the Ph. Eur. paddle test shows a mean value of above 40% by weight after one hour and that the in vitro release rate shows a mean value that is still below 80% by weight after four hours.
Type:
Grant
Filed:
April 23, 2002
Date of Patent:
October 19, 2004
Assignee:
Euro-Celtique S.A.
Inventors:
Walter Wimmer, Bianca Brogmann, Udo Hahn, Christof Spitzley
Abstract: Micellar non-aqueous or aqueous compositions for the therapeutic treatment of animal diseases caused by parasitic worms or nematodes, comprising rafoxanide and specific combinations of solvents which act as stabilising and absorption promoting agents. The solvents are selected from non-ionic surface-active agents such as Tween®-80 and from N-methylpyrrolidone, 2-pyrrolidone or dimethylsulfoxide. The compositions are easy to prepare, stable upon storage and can be administered orally, by injection or topically. With these formulations, an improvement of the efficacy of rafoxanide in the treatment of the diseases is observed.
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one linker, and at least one molecular hook wherein the molecular hook comprises a heterocyclic trimethylpyrimidinium compound.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
June 22, 2004
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne, Alan Roy Katritzky, Jon Walter Merkert
Abstract: Microparticles with adsorbed complexes of macromolecule and detergent, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(&agr;-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surfaces of the microparticles have adsorbed thereon a complex of biologically active macromolecules, such as nucleic acids, polypeptides, antigens, and adjuvants, and a detergent. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferably those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 30,000 Daltons to 70,000 Daltons. Preferred macromolecules are bacterial and viral antigens (such as HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens) as well as polynucleotides that encode for such antigens.
Type:
Grant
Filed:
September 28, 2001
Date of Patent:
June 22, 2004
Assignee:
Chiron Corporation
Inventors:
Jia-Hwa Fang, Mammohan Singh, Derek O'Hagan, Maninder Hora
Abstract: This invention defines a novel method for treatment of several neurological diseases and pathophysiologically related symptomology, said diseases including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states. An opportunity exists for pharmacological intervention in some neurological diseases by use of water soluble, small molecular weight primary amine agents and chemical derivatives thereof. Examples of such primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof.
Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
Type:
Grant
Filed:
December 15, 2000
Date of Patent:
June 1, 2004
Assignee:
The Ohio State University Research Foundation
Inventors:
Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang